HealthTree Logo
search more_vert
person Sign In / Create Account
ASH 2023: Prognostic significance of Malnutrition and sarcopenia in older adults with AML.
Posted: Feb 21, 2024
ASH 2023: Prognostic significance of Malnutrition and sarcopenia in older adults with AML. image


In recent years, there has been a growing recognition of the significance of muscle mass as a more precise nutritional indicator, surpassing traditional metrics such as BMI or serum markers. The assessment of sarcopenia, characterized by the decline in muscle mass and strength, has become pivotal in elderly patients, particularly those grappling with an oncologic diagnosis.

Utilizing advanced diagnostic tools such as CT scans and DEXA scans, researchers can effectively measure sarcopenia, shedding light on its implications for older adults, especially those diagnosed with Acute Myeloid Leukemia (AML). Watch the video or continue reading below to hear more about this study from Dr. Samuel Yates. 

Study Objective

The primary aim of this study is to evaluate the prevalence of sarcopenia and malnutrition among older adults newly diagnosed with AML and undergoing induction therapy. By delving into the intersection of nutrition, muscle health, and AML, the study seeks to uncover valuable insights into the challenges faced by this specific demographic during the early stages of treatment.

Enrollment criteria

The study encompasses a cohort of 82 newly-diagnosed AML patients currently undergoing induction at the University of Chicago Comprehensive Cancer Center. To be eligible, participants must be aged 60 or older and should not have a pacemaker or defibrillator.


As of now, the study has successfully enrolled 17 patients, with a projected completion timeline of two years from the initiation date. The ongoing nature of the investigation underscores its commitment to providing comprehensive and insightful data.

Significance of the Study

This trial holds profound importance as its outcomes could potentially advocate for the integration of nutritional assessments into the standard clinical history of all AML patients. Beyond the immediate implications for clinical practice, the study opens up new avenues for further research, emphasizing a broader focus on overall quality of life, patient well-being, and global health status. By bridging the gap between nutritional status and oncologic outcomes, this research contributes to a holistic understanding of the complex interplay between health, disease, and aging in the context of AML

HealthTree CureHub

At HealthTree, we believe that patients are powerful and have an opportunity to contribute to research in an incredibly unique way. HealthTree Cure Hub empowers patients with the knowledge to actively participate in their health journeys while providing researchers with valuable insights from real-world experiences. HealthTree Cure Hub connects patients and researchers to not only accelerate the development of innovative treatments but also lays the foundation for a future where more educated patients and research leads to more effective and personalized cures. Visit HealthTree Cure Hub today to become an active participant in your care and contribute your unique experience to researchers to move closer to a cure. 

For assistance setting up your HealthTree Cure Hub account, reach out to our patient navigation team by phone: 1-800-709-1113 or email:

The author Andrea Robles

about the author
Andrea Robles

Andrea Robles is an International Medical Graduate, part of Healthtree’s patient navigator staff. She is committed to patient’s global wellness and finding a cure through research. She’s also a wife and mom of 3.

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Astellas Pharma

Follow Us

facebook twitter